Genomic and Proteomic Study of the Inflammatory Pathway in Patients With Atrial Fibrillation and Cardiometabolic Syndrome
Atrial fibrillation (AF) and cardiometabolic syndrome (CMS) have been linked to inflammation and fibrosis. However, it is still unknown which inflammatory cytokines contribute to the pathogenesis of AF. Furthermore, cardiometabolic syndrome (CMS) risk factors such as obesity, hypertension, insulin r...
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2020-12-01
|
| Series: | Frontiers in Cardiovascular Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2020.613271/full |
| _version_ | 1818450547381895168 |
|---|---|
| author | Hana A. Itani Hana A. Itani Miran A. Jaffa Joseph Elias Mohammad Sabra Patrick Zakka Jad Ballout Amira Bekdash Rand Ibrahim Moustafa Al Hariri Mirna Ghemrawi Bernard Abi-Saleh Maurice Khoury Samir Alam Rami Mahfouz Ayad A. Jaffa Sami T. Azar Marwan M. Refaat Marwan M. Refaat |
| author_facet | Hana A. Itani Hana A. Itani Miran A. Jaffa Joseph Elias Mohammad Sabra Patrick Zakka Jad Ballout Amira Bekdash Rand Ibrahim Moustafa Al Hariri Mirna Ghemrawi Bernard Abi-Saleh Maurice Khoury Samir Alam Rami Mahfouz Ayad A. Jaffa Sami T. Azar Marwan M. Refaat Marwan M. Refaat |
| author_sort | Hana A. Itani |
| collection | DOAJ |
| description | Atrial fibrillation (AF) and cardiometabolic syndrome (CMS) have been linked to inflammation and fibrosis. However, it is still unknown which inflammatory cytokines contribute to the pathogenesis of AF. Furthermore, cardiometabolic syndrome (CMS) risk factors such as obesity, hypertension, insulin resistance/glucose intolerance are also associated with inflammation and increased level of cytokines and adipokines. We hypothesized that the inflammatory immune response is exacerbated in patients with both AF and CMS compared to either AF or CMS alone. We investigated inflammatory cytokines and fibrotic markers as well as cytokine genetic profiles in patients with lone AF and CMS. CMS, lone AF patients, patients with both lone AF and CMS, and control patients were recruited. Genetic polymorphisms in inflammatory and fibrotic markers were assessed. Serum levels of connective tissue growth factor (CTGF) were tested along with other inflammatory markers including platelet-to-lymphocyte ratio (PLR), monocyte-to-HDL ratio (MHR) in three groups of AF+CMS, AF, and CMS patients. There was a trend in the CTGF levels for statistical significance between the AF and AF+CMS group (P = 0.084). Genotyping showed high percentages of patients in all groups with high secretor genotypes of Interleukin-6 (IL-6) (P = 0.037). Genotyping of IFN-γ and IL-10 at high level showed an increase in expression in the AF + CMS group compared to AF and CMS alone suggesting an imbalance between the inflammatory and anti-inflammatory cytokines which is exacerbated by AF. Serum cytokine inflammatory cytokine levels showed that IL-4, IL-5, IL-10, IL-17F, and IL-22 were significant between the AF, AF+CMS, and CMS patients. Combination of both CMS and AF may be associated with a higher degree of inflammation than what is seen in either CMS or AF alone. Thus, the identification of a biomarker capable of identifying metabolic syndrome associated with disease will help in identification of a therapeutic target in treating this devastating disease. |
| first_indexed | 2024-12-14T20:53:02Z |
| format | Article |
| id | doaj.art-71e0044102ba460995f171cd80b17266 |
| institution | Directory Open Access Journal |
| issn | 2297-055X |
| language | English |
| last_indexed | 2024-12-14T20:53:02Z |
| publishDate | 2020-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cardiovascular Medicine |
| spelling | doaj.art-71e0044102ba460995f171cd80b172662022-12-21T22:47:46ZengFrontiers Media S.A.Frontiers in Cardiovascular Medicine2297-055X2020-12-01710.3389/fcvm.2020.613271613271Genomic and Proteomic Study of the Inflammatory Pathway in Patients With Atrial Fibrillation and Cardiometabolic SyndromeHana A. Itani0Hana A. Itani1Miran A. Jaffa2Joseph Elias3Mohammad Sabra4Patrick Zakka5Jad Ballout6Amira Bekdash7Rand Ibrahim8Moustafa Al Hariri9Mirna Ghemrawi10Bernard Abi-Saleh11Maurice Khoury12Samir Alam13Rami Mahfouz14Ayad A. Jaffa15Sami T. Azar16Marwan M. Refaat17Marwan M. Refaat18Faculty of Medicine, American University of Beirut, Beirut, LebanonDepartment of Medicine, Clinical pharmacology, Vanderbilt University Medical Center, Nashville, TN, United StatesEpidemiology and Population Health Department, Faculty of Health Sciences, American University of Beirut, Beirut, LebanonDepartment of Internal Medicine, Cardiology Division, American University of Beirut Faculty of Medicine and Medical Center, Beirut, LebanonDepartment of Internal Medicine, Cardiology Division, American University of Beirut Faculty of Medicine and Medical Center, Beirut, LebanonDepartment of Internal Medicine, Emory University Hospital, Atlanta, GA, United StatesDepartment of Internal Medicine, Cardiology Division, American University of Beirut Faculty of Medicine and Medical Center, Beirut, LebanonFaculty of Medicine, American University of Beirut, Beirut, LebanonDepartment of Internal Medicine, Cardiology Division, American University of Beirut Faculty of Medicine and Medical Center, Beirut, LebanonDepartment of Emergency Medicine, American University of Beirut Faculty of Medicine and Medical Center, Beirut, LebanonDepartment of Pathology and Laboratory Medicine, American University of Beirut Faculty of Medicine and Medical Center, Beirut, LebanonDepartment of Internal Medicine, Cardiology Division, American University of Beirut Faculty of Medicine and Medical Center, Beirut, LebanonDepartment of Internal Medicine, Cardiology Division, American University of Beirut Faculty of Medicine and Medical Center, Beirut, LebanonDepartment of Internal Medicine, Cardiology Division, American University of Beirut Faculty of Medicine and Medical Center, Beirut, LebanonDepartment of Pathology and Laboratory Medicine, American University of Beirut Faculty of Medicine and Medical Center, Beirut, LebanonDepartment of Biochemistry and Molecular Genetics, American University of Beirut Faculty of Medicine, Beirut, LebanonDepartment of Internal Medicine, Endocrinology Diabetes and Metabolism Division, American University of Beirut Faculty of Medicine and Medical Center, Beirut, LebanonDepartment of Internal Medicine, Cardiology Division, American University of Beirut Faculty of Medicine and Medical Center, Beirut, LebanonDepartment of Biochemistry and Molecular Genetics, American University of Beirut Faculty of Medicine, Beirut, LebanonAtrial fibrillation (AF) and cardiometabolic syndrome (CMS) have been linked to inflammation and fibrosis. However, it is still unknown which inflammatory cytokines contribute to the pathogenesis of AF. Furthermore, cardiometabolic syndrome (CMS) risk factors such as obesity, hypertension, insulin resistance/glucose intolerance are also associated with inflammation and increased level of cytokines and adipokines. We hypothesized that the inflammatory immune response is exacerbated in patients with both AF and CMS compared to either AF or CMS alone. We investigated inflammatory cytokines and fibrotic markers as well as cytokine genetic profiles in patients with lone AF and CMS. CMS, lone AF patients, patients with both lone AF and CMS, and control patients were recruited. Genetic polymorphisms in inflammatory and fibrotic markers were assessed. Serum levels of connective tissue growth factor (CTGF) were tested along with other inflammatory markers including platelet-to-lymphocyte ratio (PLR), monocyte-to-HDL ratio (MHR) in three groups of AF+CMS, AF, and CMS patients. There was a trend in the CTGF levels for statistical significance between the AF and AF+CMS group (P = 0.084). Genotyping showed high percentages of patients in all groups with high secretor genotypes of Interleukin-6 (IL-6) (P = 0.037). Genotyping of IFN-γ and IL-10 at high level showed an increase in expression in the AF + CMS group compared to AF and CMS alone suggesting an imbalance between the inflammatory and anti-inflammatory cytokines which is exacerbated by AF. Serum cytokine inflammatory cytokine levels showed that IL-4, IL-5, IL-10, IL-17F, and IL-22 were significant between the AF, AF+CMS, and CMS patients. Combination of both CMS and AF may be associated with a higher degree of inflammation than what is seen in either CMS or AF alone. Thus, the identification of a biomarker capable of identifying metabolic syndrome associated with disease will help in identification of a therapeutic target in treating this devastating disease.https://www.frontiersin.org/articles/10.3389/fcvm.2020.613271/fullcardiac arrhythmiacardiovascular diseasesheart diseasesatrial fibrillationinflammatory markersmetabolic syndrome |
| spellingShingle | Hana A. Itani Hana A. Itani Miran A. Jaffa Joseph Elias Mohammad Sabra Patrick Zakka Jad Ballout Amira Bekdash Rand Ibrahim Moustafa Al Hariri Mirna Ghemrawi Bernard Abi-Saleh Maurice Khoury Samir Alam Rami Mahfouz Ayad A. Jaffa Sami T. Azar Marwan M. Refaat Marwan M. Refaat Genomic and Proteomic Study of the Inflammatory Pathway in Patients With Atrial Fibrillation and Cardiometabolic Syndrome Frontiers in Cardiovascular Medicine cardiac arrhythmia cardiovascular diseases heart diseases atrial fibrillation inflammatory markers metabolic syndrome |
| title | Genomic and Proteomic Study of the Inflammatory Pathway in Patients With Atrial Fibrillation and Cardiometabolic Syndrome |
| title_full | Genomic and Proteomic Study of the Inflammatory Pathway in Patients With Atrial Fibrillation and Cardiometabolic Syndrome |
| title_fullStr | Genomic and Proteomic Study of the Inflammatory Pathway in Patients With Atrial Fibrillation and Cardiometabolic Syndrome |
| title_full_unstemmed | Genomic and Proteomic Study of the Inflammatory Pathway in Patients With Atrial Fibrillation and Cardiometabolic Syndrome |
| title_short | Genomic and Proteomic Study of the Inflammatory Pathway in Patients With Atrial Fibrillation and Cardiometabolic Syndrome |
| title_sort | genomic and proteomic study of the inflammatory pathway in patients with atrial fibrillation and cardiometabolic syndrome |
| topic | cardiac arrhythmia cardiovascular diseases heart diseases atrial fibrillation inflammatory markers metabolic syndrome |
| url | https://www.frontiersin.org/articles/10.3389/fcvm.2020.613271/full |
| work_keys_str_mv | AT hanaaitani genomicandproteomicstudyoftheinflammatorypathwayinpatientswithatrialfibrillationandcardiometabolicsyndrome AT hanaaitani genomicandproteomicstudyoftheinflammatorypathwayinpatientswithatrialfibrillationandcardiometabolicsyndrome AT miranajaffa genomicandproteomicstudyoftheinflammatorypathwayinpatientswithatrialfibrillationandcardiometabolicsyndrome AT josephelias genomicandproteomicstudyoftheinflammatorypathwayinpatientswithatrialfibrillationandcardiometabolicsyndrome AT mohammadsabra genomicandproteomicstudyoftheinflammatorypathwayinpatientswithatrialfibrillationandcardiometabolicsyndrome AT patrickzakka genomicandproteomicstudyoftheinflammatorypathwayinpatientswithatrialfibrillationandcardiometabolicsyndrome AT jadballout genomicandproteomicstudyoftheinflammatorypathwayinpatientswithatrialfibrillationandcardiometabolicsyndrome AT amirabekdash genomicandproteomicstudyoftheinflammatorypathwayinpatientswithatrialfibrillationandcardiometabolicsyndrome AT randibrahim genomicandproteomicstudyoftheinflammatorypathwayinpatientswithatrialfibrillationandcardiometabolicsyndrome AT moustafaalhariri genomicandproteomicstudyoftheinflammatorypathwayinpatientswithatrialfibrillationandcardiometabolicsyndrome AT mirnaghemrawi genomicandproteomicstudyoftheinflammatorypathwayinpatientswithatrialfibrillationandcardiometabolicsyndrome AT bernardabisaleh genomicandproteomicstudyoftheinflammatorypathwayinpatientswithatrialfibrillationandcardiometabolicsyndrome AT mauricekhoury genomicandproteomicstudyoftheinflammatorypathwayinpatientswithatrialfibrillationandcardiometabolicsyndrome AT samiralam genomicandproteomicstudyoftheinflammatorypathwayinpatientswithatrialfibrillationandcardiometabolicsyndrome AT ramimahfouz genomicandproteomicstudyoftheinflammatorypathwayinpatientswithatrialfibrillationandcardiometabolicsyndrome AT ayadajaffa genomicandproteomicstudyoftheinflammatorypathwayinpatientswithatrialfibrillationandcardiometabolicsyndrome AT samitazar genomicandproteomicstudyoftheinflammatorypathwayinpatientswithatrialfibrillationandcardiometabolicsyndrome AT marwanmrefaat genomicandproteomicstudyoftheinflammatorypathwayinpatientswithatrialfibrillationandcardiometabolicsyndrome AT marwanmrefaat genomicandproteomicstudyoftheinflammatorypathwayinpatientswithatrialfibrillationandcardiometabolicsyndrome |